Asthma Highlights From ACAAI 2021

Asthma highlights from ACAAI 2021 range from efficacy of biologic therapies to the late effects of COVID-19 in asthma patients, as reported by Dr Sandhya Khurana from the University of Rochester, in Rochester, New York.

Dr Khurana opens by discussing a study that examined real-world data to assess the effect of COVID-19 infection in asthma patients. The study found that when adjusting for age, sex, BMI, use of inhaled corticosteroids, and atopy, Latino patients, when compared with non-Latino White and Black patients, were more susceptible to prolonged respiratory inflammation after COVID-19 infection.

She then reports on a study that examined potential long-term morbidities associated with systemic corticosteroid (SCS) therapy. The study, which drew from a large administrative claims database, found that high-risk SCS exposure was associated with lifelong adverse chronic health conditions, including type 2 diabetes, hypertension, osteoporosis, and depression. Children ages 4-11 are particularly at risk.

Next, Dr Khurana highlights studies evaluating the efficacy of dupilumab and tezepelumab, two novel biologics, in asthma patients who also have allergies. Both studies demonstrated a potential benefit for a broad population of patients with severe, uncontrolled asthma.

Finally, Dr Khurana comments on ZEPHYR 2, a retrospective cohort study that looked to quantify the real-world impact of switching between biologics.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Asthma Highlights From ACAAI 2021 - Medscape - Nov 30, 2021.

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

My Alerts